NCT03867942View on ClinicalTrials.gov

BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.

PHASE1UnknownINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

May 24, 2019

Study Completion Date

August 31, 2019

Conditions

Diabetes Mellitus, Type 2Dyslipidemias

Interventions

DRUG

Monolayer group

Monolayered combination of gemigliptin and rosuvastatin

DRUG

Bilayer group

Bilayered combination of gemigliptin and rosuvastatin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LG Chem

INDUSTRY

NCT03867942 - BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination. | Biotech Hunter | Biotech Hunter